Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Leishmaniasis, Visceral

ClinicalTrials.gov lists 61 trials for Leishmaniasis, Visceral or a narrower condition beneath it.

MeSH D007898 Infections C01
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 5 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 8 Phase 3 Phase 3 13 Phase 4 Phase 4 5 Not applicable Not applicable 10 Observational Observational 19 Phase 1 Phase 1 5 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 8 Phase 3 Phase 3 13 Phase 4 Phase 4 5 Not applicable Not applicable 10 Observational Observational 19

Trials per phase

61 of the 61 trials are tagged with Leishmaniasis, Visceral itself; the rest are tagged with a narrower condition beneath it.

Get the Leishmaniasis, Visceral report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Leishmaniasis, Visceral trials start? (24)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 7

2001: 1 trials (Observational 1) 2003: 3 trials (Observational 1, Not applicable 1, Phase 3 1) 2004: 1 trials (Phase 3 1) 2005: 1 trials (Phase 1/2 1) 2006: 3 trials (Not applicable 1, Phase 2 2) 2007: 7 trials (Not applicable 1, Phase 4 2, Phase 3 1, Phase 2 2, Phase 1 1) 2008: 3 trials (Phase 3 3) 2009: 4 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 1) 2010: 3 trials (Not applicable 1, Phase 3 1, Phase 2 1) 2011: 3 trials (Not applicable 1, Phase 4 1, Phase 3 1) 2012: 1 trials (Phase 3 1) 2013: 2 trials (Not applicable 1, Phase 2 1) 2014: 5 trials (Phase 4 2, Phase 3 2, Phase 1 1) 2015: 2 trials (Observational 1, Phase 2 1) 2016: 1 trials (Not applicable 1) 2017: 1 trials (Observational 1) 2018: 4 trials (Observational 1, Phase 3 1, Phase 1 2) 2019: 2 trials (Observational 1, Phase 1 1) 2020: 2 trials (Observational 2) 2021: 1 trials (Observational 1) 2022: 3 trials (Observational 3) 2023: 2 trials (Observational 2) 2025: 4 trials (Observational 2, Not applicable 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 1
2025 4
2023 2
2022 3
2021 1
2020 2
2019 2
2018 4
2017 1
2016 1

No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: none of the 61 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Leishmaniasis, Visceral trials in? (7)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 5
Phase 1/2 1
Phase 2 8
Phase 3 13
Phase 4 5
Not applicable 10
Observational 19

How many Leishmaniasis, Visceral trials are recruiting? (5)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Recruiting 7
Active, not recruiting 1
Completed 43
Terminated 7
Unknown status 3

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Leishmaniasis, Visceral trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 2
Sichuan Huiyu Pharmaceutical Co., Ltd 2
Aurobindo Pharma Ltd 1
Bharat Serums and Vaccines Limited 1
GlaxoSmithKline 1

Which drugs are being tested for Leishmaniasis, Visceral? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Paromomycin 6
Amphotericin B Deoxycholate 5
Miltefosine 5
AMPHOTERICIN B 4

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
liposomal Amphotericine B 6
Liposomal amphotericin B + miltefosine 2
Miltefosine + Paromomycin 2
Sodium Stibogluconate 2
Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.) 1

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Leishmaniasis, Visceral trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Visceral Leishmaniasis 20 1
Pneumonia 16 1
Hypovolemic shock 2 1
Renal failure 2 1
Acute renal failure 1 1

Which publications cover Leishmaniasis, Visceral? (69)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages